Terminalia Arjuna: study protocols
9 study groups say how much Terminalia Arjuna participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
33 products in our catalogue print how much Terminalia Arjuna a serving holds.
Most common: 50 mg to 100 mg, 21% of 33 products.
| Dose per serving | Products |
|---|---|
| 10 mg to 25 mg | 6 |
| 25 mg to 50 mg | 5 |
| 50 mg to 100 mg | 7 |
| 100 mg to 250 mg | 5 |
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 3 |
| 1 g to 2.5 g | 1 |
| over 2.5 g | 2 |
Dose per serving from research
9 study groups in 8 studies say how much Terminalia Arjuna participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 56% of 9 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 2 |
| 500 mg to 1 g | 1 |
| 1 g to 2.5 g | 5 |
| 2.5 g to 5 g | 0 |
| 5 g to 10 g | 1 |
Commonly used together
None of these 9 study groups took Terminalia Arjuna with anything else.
9 study groups
| Study | |||
|---|---|---|---|
| Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate 2002 · Terminalia arjuna · Men with chronic stable angina, NYHA class II–III, and provocable ischemia on treadmill exercise testing | 1.5 g | 7 days | 58 |
| Terminalia arjuna reverses impaired endothelial function in chronic smokers 2004 · Terminalia arjuna · Male smokers, age 28.16 ± 9.45 years | 1.5 g | 2 weeks | 18 |
| Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure 1995 · Terminalia Arjuna, Phase I · 12 patients with Class IV NYHA refractory chronic congestive heart failure, related to idiopathic dilated cardiomyopathy, previous myocardial infarction, or peripartum cardiomyopathy | 1.5 g | 2 weeks | 12 |
| Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure 1995 · Terminalia Arjuna, Phase II open continuation · Phase I participants with refractory chronic congestive heart failure | 1.5 g | 2 years | 12 |
| Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial 2016 · Arjuna extract · Patients with chronic heart failure, NYHA functional class II, and LVEF ≤40%, receiving standard pharmacotherapy | 1.5 g | 12 weeks | 50 |
| Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial 2001 · Group III · Patients with coronary heart disease; age range and sex not stated | 500 mg | 30 days | 35 |
| Effect of Arjun Chāl on cardiovascular risk factors - a randomized controlled clinical trial 2021 · test group · Patients with cardiovascular risk factors; age and sex not specified | 10 g | 8 weeks | 24 |
| Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence 2015 · Terminalia arjuna group · Patients with stable coronary artery disease; age and sex not specified | 1 g | 26 weeks | — |
| Effect of E-OJ-01 on Cardiac Conditioning in Young Exercising Adults: A Randomized Controlled Trial 2017 · E-OJ-01 · Healthy males aged 18–40 years who performed regular endurance exercise | 400 mg | 8 weeks | — |